AVCT vs. OXB, ERGO, SLN, PRTC, HZD, VRP, FARN, ARIX, CIR, and BVXP
Should you be buying Avacta Group stock or one of its competitors? The main competitors of Avacta Group include Oxford Biomedica (OXB), Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Faron Pharmaceuticals Oy (FARN), Arix Bioscience (ARIX), Circassia Group (CIR), and Bioventix (BVXP). These companies are all part of the "biotechnology" industry.
Avacta Group vs. Its Competitors
Avacta Group (LON:AVCT) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.
Avacta Group has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.
In the previous week, Oxford Biomedica had 2 more articles in the media than Avacta Group. MarketBeat recorded 3 mentions for Oxford Biomedica and 1 mentions for Avacta Group. Oxford Biomedica's average media sentiment score of 1.27 beat Avacta Group's score of 0.20 indicating that Oxford Biomedica is being referred to more favorably in the news media.
Avacta Group has a net margin of -114.45% compared to Oxford Biomedica's net margin of -145.98%. Avacta Group's return on equity of -74.00% beat Oxford Biomedica's return on equity.
13.5% of Avacta Group shares are owned by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are owned by institutional investors. 54.5% of Avacta Group shares are owned by insiders. Comparatively, 41.9% of Oxford Biomedica shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Avacta Group has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Oxford Biomedica has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.
Avacta Group currently has a consensus price target of GBX 99, indicating a potential upside of 55.91%. Oxford Biomedica has a consensus price target of GBX 558, indicating a potential downside of 2.79%. Given Avacta Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Avacta Group is more favorable than Oxford Biomedica.
Summary
Avacta Group beats Oxford Biomedica on 10 of the 16 factors compared between the two stocks.
Get Avacta Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avacta Group Competitors List
Related Companies and Tools
This page (LON:AVCT) was last updated on 10/21/2025 by MarketBeat.com Staff
Free AVCT Stock Alerts